Rk Statistics

Statistical Thinking for Non-Statisticians in Drug Regulation

RK Statistics Ltd and PSI are proud to deliver Statistical Thinking for Non-Statisticians in Drug Regulation training via a unique eLearning platform.

Receive a special 10% discount on all courses.

Register for Level 1

Register for Level 2

CPD Certified

Who should enroll?

Medical Science Liaisons (MSL) | Medical Writers | Regulatory Affairs | Medical Affairs | Pharmaceutical Physicians | Clinical Investigators | Clinical Research Scientists | Statisticians transferring from other areas

Statistical Thinking for Non-Statisticians in Drug Regulation – Level 1GBP GBP

Course Agenda

This course is primarily concerned with statistical methodology for the design and analysis of clinical trials, planned and conducted within the pharmaceutical industry. Much of the methodology presented is in fact applicable on a broader basis and can be used in observational studies and in clinical trials outside of the pharmaceutical sector; nonetheless the primary context is clinical trials and pharmaceuticals.

The course is aimed at non-statisticians working in the Pharmaceutical Industry and will be suitable for physicians, investigators, clinical research scientists,medical science liaison (MSL), medical writers, regulatory personnel, statistical programmers and senior data managers. Statisticians moving from other areas of application outside of pharmaceuticals may also find the course useful in that it places the methods that they are familiar with in context for their new environment.

The course topics subdivided by section are detailed below.

1. Basic Issues in Clinical Trial Design View Demo

  • Placebo’s and Blinding
  • Randomisation
  • Signal and Noise
  • Endpoint Types
  • Superiority, Equivalence and Non-Inferiority

2. Sampling and Inferential Statistics

  • Sample and Population
  • Sample Statistics and Population Parameters
  • The Normal Distribution
  • Sampling and Standard Errors

3. Confidence Intervals and p-Values

  • Confidence Intervals
  • Hypothesis Testing
  • The p-Value
  • One-Tailed and Two-Tailed Tests

4. Intention to Treat, Analysis Sets and Missing Data

  • The Principle of ITT
  • Examples in the Application of ITT
  • The Practice of ITT
  • The Per-Protocol Set
  • Withdrawals and Missing Data

5. Diagnosis

  • Sensitivity and Specificity
  • Other Quantities
  • Prevalence
  • ROC Curves

6. Tests for Simple Treatment Comparisons

  • Statistical Testing
  • Unpaired t-Test
  • Non-Parametric Tests
  • The Chi-Squared Test for Binary Data
  • Odds Ratio and Relative Risk

7. Power and Sample Size View Demo

  • Type I and Type II Errors
  • Power
  • Calculating Sample Size
  • Link Between p-Values and Confidence Intervals

8. Multiplicity

  • Inflation of the Type I Error
  • How Multiplicity Can Arise?
  • Bonferroni Correction
  • Hochberg Correction
  • Regulatory View on Multiplicity
  • Importance of Pre-Planning
  • Avoiding Adjustment including Hierarchical Testing
  • Subgroup Testing
  • Interim Analysis

9. The Analysis of Survival Data

  • Time to Event and Censoring
  • Kaplan-Meier Curves
  • Logrank Test
  • Hazard Rate and Hazard Ratio
  • Independent Censoring

10. Equivalence and Non-Inferiority View Demo

  • Demonstrating Similarity
  • Establishing Equivalence
  • Establishing Non-Inferiority
  • Choice of Delta – Non-Inferiority
  • Switching between Non-Inferiority and Superiority

Advanced Statistical Thinking for Non-Statisticians in Drug Regulation – Level 2 GBP GBP

Course Agenda

This advanced course follows on from the introductory Level 1 course and covers more advanced topics. The Level 1 course is aimed at non-statisticians working in the pharmaceutical industry and is structured to enable the understanding of statistical concepts and methods used in the design and analysis of clinical studies. The Level 2 course is aimed at the same target audience and has the same primary objective but covers a broader and more in-depth range of topics.

The advanced course is divided into 14 sections and development follows a logical step-by-step structure. It is assumed that participants will already have completed Level 1. Each of the 14 sections concludes with a workshop-exercise to assess understanding of the material covered and a 70% mark (based on at most 2 attempts) is required on each of those exercises to receive a certificate of completion for the course.

The course topics subdivided by section are detailed below.

1. Stratifying the Analysis

  • Stratified Analysis for Continuous Endpoints
  • Cochran-Mantel-Haenszel Test for Binary Endpoints
  • Stratified Logrank Test for Time-to-Event Endpoints
  • Limitations and Extensions

2. Modelling Dependence

  • Simple Linear Regression
  • Multiple Linear Regression
  • Logistic Regression
  • Proportional Hazards Regression
  • Negative Binomial Regression
  • Univariate versus Multivariate
  • Correlation

3. Modelling for Treatment Comparisons View Demo

  • Analysis of Covariance (ANCOVA)
  • Regression Towards the Mean
  • Least Squares Mean
  • Treatment x Covariate Interactions
  • Prognostic versus Predictive
  • Modelling
    • Logistic Regression
    • Negative Binomial Regression
    • Cox Proportional Hazards Model

4. Missing Data and Imputation

  • Avoiding Missing Data
  • Classifying Missing Data
    • Missing Completely at Random
    • Missing at Random
    • Missing Not at Random
  • Multiple Imputation
  • Pattern Mixture Models
  • MMRM for Repeated Measures

5. Estimands View Demo

  • Estimands:
    • What are they?
    • Why are they interesting?
  • Estimand Strategies
    • Treatment Policy
    • Hypothetical
    • Composite
    • Principal Stratum
    • While On-Treatment
  • Case Study in Diabetes

6. Multiplicity 2

  • Recap Level 1, Section 8
    • Golden Rule
    • Reporting p-Values
  • Combining Hierarchical and α-Splitting Methodologies
  • Closed Testing with Case Studies
  • Revisiting Workshop-Exercise Level 1, Section 8
  • Exploratory Analyses
  • Revisiting Interim Analyses

7. Bayesian Statistics

  • Frequentist versus Bayesian Methodologies
  • Bayes Rule
  • Prior and Posterior Distributions
  • Case Study – Ovarian Cancer
  • Practical Applications

8. Meta-Analysis View Demo

  • Objectives of Meta-Analysis
  • General Aspects of Conduct
  • Fixed and Random Effects
  • Meta-Analysis versus Pooling
  • Assessing Heterogeneity
  • Publication Bias and Funnel Plots

9. Network Meta-Analysis

  • Network Meta-Analysis (NMA) for Indirect Comparisons
  • Case Study – Psoriasis
  • Network Geometry
  • Bayesian Rank Analysis
  • Surface Under the Cumulative Ranking (SUCRA) Curve
  • Indirect Comparisons and Effect Modifiers
  • NMA versus Meta-Analysis

10. Survival Data 2

  • Recap, Level 1, Section 9
  • Proportional Hazards Assumption
  • Restricted Mean Survival Time
  • Accounting for Cross-Over
  • Cumulative Incidence Functions

11. Observational Studies and Propensity Scoring

  • Observational Studies and Forms of Bias
  • Regulatory Acceptance
  • Real-World Evidence
  • Selection Bias in Observational Studies
  • Propensity Score Matching
  • Case Study
  • Stratification and Inverse Propensity Score Weighting

12. Statistical Aspects of Safety Data

  • Primary Endpoint Safety
  • Safety Data at the Trial level
  • Incidence Rates
  • Tables and Graphs for Reporting
  • Data and Safety Monitoring Boards (DSMBs)
  • Signal Detection
    • Proportional Reporting Ratios
    • Bayesian Neural Networks

13. Equivalence and Non-Inferiority 2

  • Recap, Level 1, Section 10
  • p-Values for Non-Inferiority and Equivalence
  • Assay Sensitivity
  • Sample Size – Non-Inferiority
  • Analysis Sets
  • Bioequivalence
  • Biosimilarity
  • Case Study– Neovascular AMD

14. Adaptive Designs

  • Definition of Adaptive Designs
  • Restricted and Flexible Adaptations
  • Type I Error Control using a Combination Test
  • Operational Bias
  • Increasing Sample Size
  • Seamless Phase I/Phase II
  • Changing the Primary Endpoint
  • Enrichment

'Access to the 2nd edition of Richard kay's book 'Statistical Thinking for Non-Statisticians in Drug Regulation'  in eBook format will be included as part of the Advanced level package at no extra cost. The book published by Wiley is widely recognised as a leading text in the field.'